Search results
Showing 31 to 38 of 38 results for secukinumab
See a complete list of all our guidance and quality standards currently open for consultation
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults.
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Discontinued Reference number: GID-TA10598
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]
In development Reference number: GID-TA11761 Expected publication date: TBC
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.